Ptc Therapeutics, Inc.PTCT

PTC Therapeutics Inc. (NASDAQ: PTCT) spent the first quarter of 2026 burning $59 million in operating cash while reporting $272.6 million in revenue, leaving a net loss of $2.8 million and a technical balance-sheet deficit of $180.5 million. The company’s stockholders’ equity now reads -$180.5 million, despite holding $834 million in cash and $2.87 billion in total assets; liabilities, meanwhile, have swollen to $3.05 billion. The filing is a reminder that a biotech’s pipeline slides don’t always square with its bank balance.

Evrysdi®, the spinal muscular atrophy therapy developed with Roche and sold in partnership with the SMA Foundation, remains the company’s marquee product, occupying pride of place on the “Our Products” page. The drug’s commercial success is real enough to drive $272.6 million in quarterly revenue, but the company’s latest 10-Q shows that revenue was consumed by $100.9 million in R&D and $103.8 million in other expenses, leaving operating income of $45 million only because the firm chose not to label more of its costs as operating. Inventory, net, sits at $75.6 million, down $2.6 million from the prior period-hardly the stuff of blockbuster biotech balance sheets.

The company’s science pages boast two platforms-splicing and inflammation/ferroptosis-with a focus on rare diseases, but the latest 10-Q tells a different story. Revenue from contracts with customers, excluding tax, was $272.6 million for the quarter ending 31 March 2026; net income attributable to the parent was -$2.8 million; operating income was $45.0 million; stockholders’ equity was -$180.5 million; cash and equivalents stood at $834.0 million; net cash used in operating activities was -$59.0 million; R&D expense was $100.9 million; and weighted average diluted shares outstanding were 82.5 million, yielding a loss of $0.03 per share. The company’s cash burn, inventory dynamics, and technical insolvency are the numbers that matter most to anyone holding the stock or the debt.

The company’s June 2026 indenture, filed with the SEC, includes a conversion feature that can be triggered if the stock trades below a threshold for 25 consecutive days, at which point noteholders can demand conversion at 98% of the last reported sale price. The fine print is a reminder that even a $834 million cash pile doesn’t inoculate creditors against downside scenarios when the balance sheet’s equity column is already underwater.

What changed this week: five insider filings in nine days logged dispositions or sales of shares by directors and officers, including a single block worth nearly $10 million. The filings are routine filing trail, but the timing-amid a technically insolvent balance sheet-raises the question of how much dry powder the C-suite still believes it has left. The company’s product pages, science summaries, and newsroom remain polished and aspirational; the 10-Q is what the company actually collected this quarter. The tension between the two is the story.

The SEC filings and XBRL company facts data are the primary rails for this report; they provide the only audited numbers used here. The product pages and science summaries are useful for understanding what the company sells and how it frames its work, but they do not change the balance-sheet arithmetic. The indenture terms and insider filings are sourced from SEC EDGAR; they establish the legal and governance context but do not alter the financial outcome already captured in the 10-Q.